The double chin might be a fat profit center for pharmaceutical giant Allergan.
Scientists at Kythera Biopharmaceuticals worked for roughly a decade on Kybella, an injectable treatment for what you probably think of as your jowls. After the FDA approved the chin treatment in April 2015, Allergan bought Kythera for $2.1 billion in cash and it is now putting together a September ad blitz.
Kybella's active ingredient, deoxycholic acid, is a form of bile that destroys fat cells in the digestive tract and, it turns out, in the chin.
The treatment involves 20 to 30 tiny injections by a doctor, who must avoid nerves and blood vessels under the jaw. Most patients require two to four sessions, each reportedly costing $1,500.
Kybella will increase Allergan's position in the booming market for aesthetic treatment. The company sells Botox for eye wrinkles and Voluma as a dermal filler for cheekbones.
© Copyright (c) 2016 Sound Publishing Inc., The Herald Business Journal. All rights reserved., source Journals